AstraZeneca on Thursday announced that the Food and Drug Administration approved Brilinta (ticagrelor) tablets at a 60 mg dose for patients with a history of heart attack beyond the first year.
A new study conducted by researchers at CVS Caremark and Brigham and Women's Hospital explored the impact of genetic testing on prescribing patterns for cardiovascular therapy.
A Food and Drug Administration expert panel has recommended against expanding the approval of a Johnson & Johnson drug, the company said.
Walmart and Sam's Club will be among the first retailers to offer a generic version of an antiplatelet drug.
A recent clinical trial involving a new drug formulation incorporating aspirin with soy-derived phosphatidylcholine found that the drug combination significantly can reduce irritation to the stomach and upper gastrointestinal tract.